Bristol-Myers Squibb (NYSE:BMY) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 8.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 378,934 shares of the biopharmaceutical company’s stock after selling 36,181 shares during the period. D.A. Davidson & CO.’s holdings in Bristol-Myers Squibb were worth $19,606,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of BMY. FMR LLC increased its stake in shares of Bristol-Myers Squibb by 10.5% during the third quarter. FMR LLC now owns 44,940,609 shares of the biopharmaceutical company’s stock valued at $2,325,227,000 after acquiring an additional 4,275,787 shares during the period. Summit Financial Wealth Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 2.4% in the 3rd quarter. Summit Financial Wealth Advisors LLC now owns 9,658 shares of the biopharmaceutical company’s stock worth $500,000 after buying an additional 225 shares in the last quarter. Dai ichi Life Insurance Company Ltd boosted its stake in Bristol-Myers Squibb by 308.7% during the third quarter. Dai ichi Life Insurance Company Ltd now owns 66,197 shares of the biopharmaceutical company’s stock valued at $3,425,000 after buying an additional 50,000 shares in the last quarter. Patton Albertson Miller Group LLC acquired a new position in Bristol-Myers Squibb during the third quarter worth about $246,000. Finally, The Manufacturers Life Insurance Company raised its position in Bristol-Myers Squibb by 1.8% in the third quarter. The Manufacturers Life Insurance Company now owns 1,711,074 shares of the biopharmaceutical company’s stock worth $88,531,000 after acquiring an additional 29,480 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.2 %

Shares of NYSE:BMY opened at $58.73 on Tuesday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The firm has a market capitalization of $119.11 billion, a P/E ratio of -16.36, a price-to-earnings-growth ratio of 15.79 and a beta of 0.44. The firm has a fifty day moving average of $53.83 and a two-hundred day moving average of $47.87.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter in the previous year, the company posted $2.00 earnings per share. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. On average, equities analysts expect that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.09%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s payout ratio is presently -66.85%.

Analyst Ratings Changes

BMY has been the topic of several recent research reports. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Daiwa Capital Markets raised Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. UBS Group boosted their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 9th. Finally, BMO Capital Markets increased their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $54.07.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,830 shares of the business’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.